Article | Published:

Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy


MicroRNAs (miRNAs) are widely expressed in organisms and are implicated in the regulation of most biological functions. The present study investigated the association of plasma miRNAs with the clinical outcomes of dual antiplatelet therapy in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Plasma miRNA levels were screened using high-throughput Illumina sequencing to evaluate the antiplatelet efficacy of clopidogrel and aspirin. Six plasma miRNAs (miR-126, miR-130a, miR-27a, miR-106a, miR-21, and miR-142) were associated with clopidogrel-treated platelet aggregation. These miRNAs were validated in a prospective cohort of 1230 CAD patients using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). High plasma miR-142 levels were associated with a high risk of major adverse cardiovascular events (MACE), with a hazard ratio (95% confidence interval) of 1.83 (1.30–2.59) at a false discovery rate of <5%. Multivariable Cox regression analysis revealed that diabetes mellitus, heart failure, calcium channel blocker application, and a high plasma miR-142 level were independent risk factors of MACE. The levels of the six plasma miRNAs were not significantly associated with bleeding events during the 3-year follow-up. In conclusion, plasma miR-142 is potential marker to predict MACE in CAD patients after PCI.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Ethics declarations

Competing interests

The authors declare no competing interests


  1. 1.

    Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 2015;8:43–61.

  2. 2.

    Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.

  3. 3.

    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

  4. 4.

    Romaine SP, Tomaszewski M, Condorelli G, Samani NJ. MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart. 2015;101:921–8.

  5. 5.

    Berezikov E, Cuppen E, Plasterk RH. Approaches to microRNA discovery. Nat Genet. 2006;38:S2–7.

  6. 6.

    Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastas. 2009;28:369–78.

  7. 7.

    Serebruany VL, Atar D. Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol. 2007;99:288–90.

  8. 8.

    Davila CD, Vargas F, Huang KH, Monaco T, Dimou A, Rangaswami J, et al. Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets. 2015;26:651–6.

  9. 9.

    Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13:358–69.

  10. 10.

    Kang K, Peng X, Luo J, Gou D. Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling. J Anim Sci Biotechnol. 2012;3:4.

  11. 11.

    Oka S, Furukawa H, Shimada K, Hashimoto A, Komiya A, Fukui N, et al. Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet Disord. 2017;18:21.

  12. 12.

    Wang R, Hong J, Cao Y, Shi J, Gu W, Ning G, et al. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. Eur J Endocrinol. 2015;172:291–300.

  13. 13.

    Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang Q, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol Rep. 2014;31:1863–70.

  14. 14.

    Liu T, Zhong S, Rao F, Xue Y, Qi Z, Wu S. Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients. Europace. 2016;18:92–9.

  15. 15.

    Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–6.

  16. 16.

    Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401–14.

  17. 17.

    Merkerova M, Belickova M, Bruchova H. Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol. 2008;81:304–10.

  18. 18.

    Xu R, Bi C, Song J, Wang L, Ge C, Liu X, et al. Upregulation of miR-142-5p in atherosclerotic plaques and regulation of oxidized low-density lipoprotein-induced apoptosis in macrophages. Mol Med Rep. 2015;11:3229–34.

  19. 19.

    Sharma S, Liu J, Wei J, Yuan H, Zhang T, Bishopric NH. Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO Mol Med. 2012;4:617–32.

  20. 20.

    Barsanti C, Trivella MG, D’Aurizio R, El Baroudi M, Baumgart M, Groth M, et al. Differential regulation of microRNAs in end-stage failing hearts is associated with left ventricular assist device unloading. Biomed Res Int. 2015;2015:592512.

  21. 21.

    Pienimaeki-Roemer A, Konovalova T, Musri MM, Sigruener A, Boettcher A, Meister G, et al. Schmitz G. Transcriptomic profiling of platelet senescence and platelet extracellular vesicles. Transfusion. 2017;57:144–56.

  22. 22.

    Jiao M, You HZ, Yang XY, Yuan H, Li YL, Liu WX, et al. Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy. Sci Rep. 2018;8:724.

  23. 23.

    Wang N, Zhang L, Lu Y, Zhang M, Zhang Z, Wang K, et al. Down-regulation of microRNA-142-5p attenuates oxygen-glucose deprivation and reoxygenation-induced neuron injury through up-regulating Nrf2/ARE signaling pathway. Biomed Pharmacother. 2017;89:1187–95.

  24. 24.

    Zhan L, Lei S, Li W, Zhang Y, Wang H, Shi Y, et al. Suppression of microRNA-142-5p attenuates hypoxia-induced apoptosis through targeting SIRT7. Biomed Pharmacother. 2017;94:394–401.

  25. 25.

    Kee HJ, Park S, Kwon JS, Choe N, Ahn Y, Kook H, et al. B cell translocation gene, a direct target of miR-142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression. FEBS Lett. 2013;587:2385–92.

  26. 26.

    Kaudewitz D, Skroblin P, Bender LH, Barwari T, Willeit P, Pechlaner R, et al. Association of MicroRNAs and YRNAs with platelet function. Circ Res. 2016;118:420–32.

  27. 27.

    Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013;112:595–600.

  28. 28.

    Shi R, Zhou X, Ji WJ, Zhang YY, Ma YQ, Zhang JQ, et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. Biomed Res Int. 2015;2015:981841.

  29. 29.

    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2010;96:186–9.

  30. 30.

    Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013;6:1275–81.

  31. 31.

    Goodman SG, Clare R, Fau-Pieper KS, Pieper Ks, Fau-Nicolau JC, Nicolau Jc, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125:978–86.

Download references


This work was supported by the National Key R&D program (No 2017YFC0909301 and 2016YFC0905003), National Natural Science Foundation of China (No 81673514, 81373486, 81202602, and 81470440), Science and Technology Development Projects of Guangdong Province, China (No 2016B090918114), and Science and Technology Development Projects of Guangzhou, Guangdong, China (201510010236 and 201604020096).

Authors contributions

SZ, YH, QT, HL, and HW designed the research. QT, HL, and HW performed the experiments and wrote the article. SZ, YH, and QT analyzed the data. Other colleagues helped collect the sample and clinical data. All authors have read and approved the final manuscript.

Author information

Competing interests

The authors declare no competing interests

Correspondence to Ya-ling Han or Shi-long Zhong.

Electronic supplementary material

Supplementary Tables

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • plasma miRNAs
  • miR-142
  • antiplatelet therapy
  • MACEs
  • coronary artery disease
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5